More than 500 million people worldwide are living with chronic hepatitis B or C infection, making viral hepatitis many times more common than HIV. Chronic infection with the hepatitis B or C viruses can lead to serious and life-threatening liver damage, including liver cirrhosis (scarring), liver cancer and the need for liver transplantation. 

  • Hepatitis C virus (HCV) is one of the leading causes of preventable death globally, with more than 350,000 deaths each year attributable to HCV-related liver disease or cancer.
  • Hepatitis B virus (HBV) is especially common in China and other Asian countries where infant immunization for the disease is not yet routine. HBV is second only to tobacco as a cancer-causing agent.
  • Many people with viral hepatitis have not been diagnosed, and the vast majority has not received medical treatment for the disease.

Our Role

Gilead has developed today’s leading medicines for viral hepatitis.

Sovaldi® (sofosbuvir), given in combination with ribavirin with or without pegylated interferon (depending on the viral genotype), is recommended by the World Health Organization for the treatment of chronic hepatitis C infection.  Gilead is working with regional partners to introduce branded Sovaldi in low- and middle-income countries, prioritizing those with the greatest disease burden. The company works with generic drug manufacturers in India to produce high-quality, low-cost generic Sovaldi for use in 91 developing countries.

Viread® (tenofovir disoproxil fumarate) is indicated for the treatment of chronic hepatitis B. We work with regional business partners and generic licensing partners to sell Viread for HBV at discounted prices in more than 125 developing countries. We are working to increase the number of access countries in which Viread is registered for HBV.

At Gilead we are inspired by the opportunity to address unmet medical needs for patients living with life-threatening diseases around the world.

More Information